Wuxi Biocity Biopharmaceutics

BioCity Biopharmaceutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Wuxi, China. The company focuses on developing innovative, modality-independent therapeutics for oncology and nephropathy, including small molecules, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Its lead candidate, SC0062, is a highly selective endothelin receptor type A (ETA) antagonist currently in Phase 3 trials for IgA nephropathy and Phase 2 for diabetic kidney disease. BioCity's oncology pipeline features several first-in-class assets, such as ADCs targeting CDH3 and GPC3, as well as inhibitors for the DNA damage response pathway (WEE1 and ATR). The company has established strategic collaborations with global pharmaceutical leaders like AstraZeneca and Merck to evaluate combination therapies in advanced cancers.